July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Parafoveal retinal sensitivity in branch retinal vein occlusion after anti-VEGF therapy
Author Affiliations & Notes
  • Ryutaro Tomita
    Ophthalmology, Fukushima Medical University, Fukushima, Fukushima, Japan
  • Akira Ojima
    Ophthalmology, Fukushima Medical University, Fukushima, Fukushima, Japan
  • Yutaka Kato
    Ophthalmology, Fukushima Medical University, Fukushima, Fukushima, Japan
  • Tetsuju Sekiryu
    Ophthalmology, Fukushima Medical University, Fukushima, Fukushima, Japan
  • Footnotes
    Commercial Relationships   Ryutaro Tomita, None; Akira Ojima, None; Yutaka Kato, None; Tetsuju Sekiryu, Novartis (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4285. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ryutaro Tomita, Akira Ojima, Yutaka Kato, Tetsuju Sekiryu; Parafoveal retinal sensitivity in branch retinal vein occlusion after anti-VEGF therapy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4285.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate parafoveal retinal sensitivity (RS) in eyes with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) after anti-vascular endothelial growth factor treatment in Japanese patients.

Methods : A prospective case series. Thirty eyes of 30 patients with newly treated BRVO-ME were evaluated; 12 males and 18 females, mean age 69.3 years old. All patients underwent ophthalmic examination including measurement of the best corrected visual acuity (BCVA) and evaluation of the fovea using optical coherence tomography (OCT) (Cirrus OCT, Carl-Zeiss, Germany). All eyes were treated with intravitreal injection of ranibizumab (IVR) as the initial treatment and received as needed dosing during 3 months follow-up period. Retreatment criteria was mean central subfield thickness (CST) exceeding 300 μm. Parafoveal RS was measured at 3, 5, and 8 degrees superior and inferior from the fovea (i.e. 6 points per a patient) using microperimeter (MP-3, NIDEK, Japan) at baseline and month 3. Measurement points were classified into 3 groups; O groups which located inside of BRVO area, ME groups which showed ME or serous retinal detachment (SRD) but located outside of BRVO area, N group which showed no pathologic findings. Changes of RS after treatment were evaluated.

Results : The mean number of IVR during 3 months was 2.1 times. The mean logMAR improved from 0.48 at baseline to 0.23 at month 3 (p<0.01). The average of CST decreased from 521µm at baseline to 304µm at month 3 (p<0.01). In all 180 measurement point, number of points in O, ME, and N group were 76, 62, and 42, respectively. In 76 points of O group, all points showed ME, 47 points showed SRD, and 53 points showed retinal or subretinal hemorrhage. RS of O, ME, and N group were 11.8, 23.1, and 25.9 dB at baseline and 17.3, 26.3, 26.5 dB at month 3, respectively. After 3 month, no SRD was found in any points. In 76 points of O group, hemorrhage disappeared in 35 points and remained in 18 points, ME disappeared in 46 points and remained in 30 points, improvement of RS were 6.2, 4.3, 7.3, 2.8 dB, respectively.

Conclusions : Regardless of BRVO area or not, decrease of exudation after IVR caused improvement of parafoveal RS. Disappearance of ME showed stronger contribution for improvement of RS than disappearance of hemorrhage.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×